Status:
COMPLETED
Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19
Lead Sponsor:
Universidad Peruana Cayetano Heredia
Conditions:
SARS-CoV-2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether hydroxychloroquine is an effective prophylactic regimen to prevent SARS-CoV-2 infection among healthcare workers. Participants will be randomized into...
Eligibility Criteria
Inclusion
- Healthcare workers in service during the COVID-19 outbreak including medical, nurse, technical, and auxiliary staff.
- Negative rapid serologic and molecular testing for SARS-CoV-2.
- Written informed consent.
Exclusion
- Presents COVID-19 symptoms including cough, fever, myalgias, headaches, loss of smell, and taste.
- Prior (last 30 days), current or planned use (during study period) of hydroxychloroquine, chloroquine sulfate, or azithromycin.
- Known cardiac disease or a history of prolonged QT syndrome.
- Known allergy or intolerance to hydroxychloroquine and/or chloroquine sulfate.
- Use of concomitant medications that are contraindicated with the use of hydroxychloroquine.
- Other reported medical conditions, such as glucose-6-phosphate dehydrogenase deficiency, hepatic or renal insufficiency, or visual acuity or field disturbances, that make study participation not in the individual's best interest.
Key Trial Info
Start Date :
June 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 23 2020
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04414241
Start Date
June 25 2020
End Date
November 23 2020
Last Update
October 28 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro Médico Naval "Cirujano Mayor Santiago Távara"
Callao, Peru, 07006
2
Hospital Nacional Arzobispo Loayza
Lima, Peru, 15082
3
Hospital Cayetano Heredia
Lima, Peru, 15102